Published in Antimicrob Agents Chemother on October 06, 2014
Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World J Emerg Surg (2016) 1.55
Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method. Antimicrob Agents Chemother (2015) 0.99
Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection. Antimicrob Agents Chemother (2015) 0.92
Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLoS One (2016) 0.87
Clinical perspectives on echinocandin resistance among Candida species. Curr Opin Infect Dis (2015) 0.87
Update on Antifungal Drug Resistance. Curr Clin Microbiol Rep (2015) 0.87
Echinocandin resistance in Candida spp. isolated from liver transplant recipients. Antimicrob Agents Chemother (2016) 0.87
Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study. Antimicrob Agents Chemother (2015) 0.78
In vitro exposure to increasing micafungin concentrations easily promotes echinocandin resistance in Candida glabrata isolates. Antimicrob Agents Chemother (2016) 0.77
A multi-center study of method-dependent epidemiological cutoff values (ECVs) for resistance detection in Candida spp. and Aspergillus spp. to amphotericin B and echinocandins for the Etest agar diffusion method. Antimicrob Agents Chemother (2016) 0.77
Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplant Direct (2017) 0.75
Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model. Antimicrob Agents Chemother (2017) 0.75
Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum. Mycopathologia (2017) 0.75
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect (2011) 17.47
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis (2012) 5.83
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis (2013) 4.14
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother (2013) 2.14
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother (2005) 2.07
Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother (2013) 1.49
Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother (2004) 1.48
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother (2012) 1.47
FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis (2014) 1.30
Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother (2014) 1.21
Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance. Antimicrob Agents Chemother (2013) 1.06
In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother (2006) 1.02
Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies. Expert Rev Anti Infect Ther (2014) 0.90
Candida peritonitis: an update on the latest research and treatments. World J Surg (2011) 0.90
Treatment of candidal cholangitis with caspofungin therapy in a patient with a liver transplant: documentation of biliary excretion of caspofungin. Clin Infect Dis (2004) 0.85
Candida glabrata intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses. Infect Immun (2014) 0.84
Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother (2011) 0.81
Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother (2016) 1.22
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother (2015) 1.14
Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. Antimicrob Agents Chemother (2014) 1.12
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates. Antimicrob Agents Chemother (2016) 0.98
Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection. Antimicrob Agents Chemother (2015) 0.92
Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother (2016) 0.92
In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases. Antimicrob Agents Chemother (2017) 0.84
KPC-producing Klebsiella pneumoniae strains that harbor AAC(6')-Ib exhibit intermediate resistance to amikacin. Antimicrob Agents Chemother (2014) 0.83
Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother (2017) 0.76
Rapid detection of FKS-associated echinocandin resistance in Candida glabrata. Antimicrob Agents Chemother (2016) 0.76
Erratum for Shields et al., Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection. Antimicrob Agents Chemother (2016) 0.75